With respect to tolerability concerns with the recommended paliperidone palmitate initiation dosing, this study did not reveal unexpected adverse events or high rates of specific adverse events in the ...
Every-6-month dosing of the long-acting injectable paliperidone palmitate (Invega Hafyera) for schizophrenia was effective and safe up to 3 years, researchers reported during a poster presentation at ...
The extended-release delivery coupled with the 351mg dose allows for single-dose initiation. Erzofri ® (paliperidone palmitate) extended-release injectable suspension is now available for the ...
In a 2022 decision involving Janssen and Pharmascience, the Federal Court found that the claims of Canadian Patent No. 2,655,335 (335 patent, relating to paliperidone palmitate (Janssen’s INVEGA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results